A Single-dose, Open-label Parallel Study to Assess the Pharmacokinetics of RLX030 in Subjects With Mild, Moderate and Severe Hepatic Impairment Compared to Healthy Control Subjects
Phase of Trial: Phase I
Latest Information Update: 16 Dec 2014
At a glance
- Drugs Serelaxin (Primary)
- Indications Acute heart failure; Chronic heart failure; Heart failure
- Focus Pharmacokinetics
- 05 Mar 2012 Actual end date (Dec 2011) added as reported by ClinicalTrials.gov.
- 05 Mar 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 16 Sep 2011 New trial record